We have several scenarios in chronic #lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a PFS regulatory driven study. In absence of cure/OS the real question for patients/doctors is AB followed by C at relapse (PFS2) vs ABC (PFS1) all together #ASH24

Practical approach to R/R Hodgkin lymphoma management #ASH24

#lymsm #ASH24 oral abstract: Duvelisib + Ruxolitinib for PTCL, phase 1. Favorable side effect profile even compared with single agent duvelisib (less pneumonitis). ORR 45%, CR 22%. Great responses in AITL/TFH! Lymphoma Hub Hem-Onc Fellows Network AHN Hematology/Oncology Fellowship

#lymsm #ASH24 The EBMT lymphoma working party analysis of auto and allo SCT for PTCL. Given paucity of data, It’s important to see this real world data to support current practice. ASCT in CR1 is important and allo-SCT can save lives in relapsed setting Lymphoma Hub

CONGRESS | #ASH24 | PRESENTATION Martin Hutchings, University of Copenhagen shared extended follow-up data from the phase Ib/II trial of glofitamab + polatuzumab in patients with R/R LBCL including HGBCL. After a median follow-up of 28.2 months, glofitamab + polatuzumab continued to

Are you feeling revitalized? 🎇 #ASH24 has been an incredible reminder of why we do what we do. The knowledge and inspiration gained here will undoubtedly lead to exciting advances as we return home to apply what we've learned. Here's to a fantastic final day in San Diego!

Get ready for two lymphoma #ASH24 LBAs this morning! #lymsm

inMIND: R/R FL, Tafa+R2 vs R2, presented by Laurie Sehn , 57% reduction in risk of progression/relapse/death. PFS advantage met. I'm curious on antigen loss data as sequencing for CAR-T will be important. #LBA1 #ASH24 #Lymsm

Great results and well conducted study! It’s convincing enough for me! #lymsm #ASH24 Lymphoma Hub AHN Hematology/Oncology Fellowship Hem-Onc Fellows Network 👏👏

Meaningful use of MRD in #MCL. We probably should not transplant patients with uMRD after induction. #lymsm #ASH2024 @chelseap_DO AHN Hematology/Oncology Fellowship Hem-Onc Fellows Network

Shining bright at ASH !Huge congratulations to our amazing residents for their outstanding poster presentations at the ASH Conference. Your hard work and dedication inspire us all—way to represent! AHN AHN Hematology/Oncology Fellowship Yazan Samhouri MD

That’s a wrap on #ASH24! A big thank you to ASH for an inspiring conference. It was fantastic connecting with friends, collaborators, and colleagues. Now, it's back to Pittsburgh to continue advancing patient care and pushing the field forward!

Had the privilege of speaking on cellular therapy at the University of Kentucky’s Annual Review of Hematology and Immunotherapy. Incredible discussions, great people, and a fantastic opportunity to catch up with friends. Let’s bring #TILs to Kentucky! 💪🏻 #CellTherapy AHN

Celebrating the graduation of our incredible fellows!Your hard work, compassion, and commitment to excellence inspire us all.We are so proud of the physicians, colleagues, and leaders you’ve become.Wishing all 4 continued success—you will always be part of our HemOnc family! 🩸🧬